Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03713424 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

An fMRI Study of the Effects of Clavulanic Acid on Drug Addiction

StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 12 months later Aug 31, 2026 → Aug 31, 2027
See other at-risk trials from University of Missouri-Columbia

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary and study completion pushed from Aug 31, 2026 to Aug 31, 2027
    • Enrollment closed, study ongoing
    • Eligibility criteria expanded, about 19 words
    • Site details revised
  2. Primary completion date: Aug 31, 2024 to Aug 31, 2026
    • Study completion date: Dec 31, 2024 to Aug 31, 2026
    v14
  3. Primary endpoints: 3 to 2
    • Secondary endpoints expanded, about 20 words
    v13
  4. Primary completion date: Aug 31, 2022 to Aug 31, 2024
    • Study completion date: Dec 31, 2022 to Dec 31, 2024
    v12
  5. Re-verified, no change to tracked fieldsv11
Show 9 earlier versionsHide 9 earlier versions
  1. Lead sponsor: Medical University of South Carolina to University of Missouri-Columbiav10 Show 5 more changesShow less
    • Primary completion date: Jun 30, 2022 to Aug 31, 2022
    • Study completion date: Jun 30, 2022 to Dec 31, 2022
    • Eligibility criteria expanded, about 112 words
    • Study site revised
    • Study title expanded, about 3 words
  2. Primary and study completion dates: Jun 30, 2021 to Jun 30, 2022v9
  3. Primary completion date: Mar 31, 2020 to Jun 30, 2021
    • Study completion date: May 2020 to Jun 30, 2021
    v8
  4. Primary completion date: Jan 2020 to Mar 31, 2020v7
  5. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date changed from estimate of Feb 2019 to Mar 26, 2019
    v6
  6. Start date: Jan 2019 to Feb 2019v5
  7. Start date: Dec 2018 to Jan 2019v4
  8. Start date: Nov 2018 to Dec 2018v3
  9. Primary endpoints revised (3)
    • Study title shortened, about 3 words
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This research study is looking into the effects of clavulanic on smoking behavior in adult cigarette smokers. The primary study hypothesis is that, compared to placebo, clavulanic acid will reduce smoking over the course of the study.
Trial Details
NCT Number NCT03713424
Lead Sponsor University of Missouri-Columbia
Conditions
(from sponsor)		 Tobacco Use Disorder
Related terms Tobacco Use Disorder
Enrollment 30 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov